SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-23-108292
Filing Date
2023-10-10
Accepted
2023-10-10 16:06:59
Documents
13
Period of Report
2023-09-13
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm2327255d1_8ka.htm   iXBRL 8-K/A 26981
2 EXHIBIT 10.1 tm2327255d1_ex10-1.htm EX-10.1 336628
  Complete submission text file 0001104659-23-108292.txt   604832

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fwbi-20230913.xsd EX-101.SCH 3027
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fwbi-20230913_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fwbi-20230913_pre.xml EX-101.PRE 22367
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2327255d1_8ka_htm.xml XML 3837
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
First Wave BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 464993860 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-37853 | Film No.: 231318005
SIC: 2834 Pharmaceutical Preparations